$288 Million is the total value of Octagon Capital Advisors LP's 31 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | New | APELLIS PHARMACEUTICALS INC | $31,367,000 | – | 548,374 | +100.0% | 10.87% | – |
| IMAB | New | I MABsponsored ads | $21,432,000 | – | 454,550 | +100.0% | 7.43% | – |
| CLDX | New | CELLDEX THERAPEUTICS INC NEW | $18,245,000 | – | 1,041,398 | +100.0% | 6.32% | – |
| CRIS | New | CURIS INC | $18,018,000 | – | 2,200,000 | +100.0% | 6.25% | – |
| FDMT | New | 4D MOLECULAR THERAPEUTICS IN | $15,659,000 | – | 377,777 | +100.0% | 5.43% | – |
| PMVP | New | PMV PHARMACEUTICALS INC | $15,378,000 | – | 250,000 | +100.0% | 5.33% | – |
| ARVN | New | ARVINAS INC | $15,160,000 | – | 178,500 | +100.0% | 5.26% | – |
| GOSS | New | GOSSAMER BIO INC | $15,116,000 | – | 1,563,138 | +100.0% | 5.24% | – |
| XLRN | New | ACCELERON PHARMA INC | $14,376,000 | – | 112,363 | +100.0% | 4.98% | – |
| CCXI | New | CHEMOCENTRYX INC | $13,937,000 | – | 225,076 | +100.0% | 4.83% | – |
| CRDF | New | CARDIFF ONCOLOGY INC | $11,694,000 | – | 650,000 | +100.0% | 4.05% | – |
| RNA | New | AVIDITY BIOSCIENCES INC | $10,975,000 | – | 430,041 | +100.0% | 3.80% | – |
| DYN | New | DYNE THERAPEUTICS INC | $10,112,000 | – | 481,538 | +100.0% | 3.50% | – |
| TSHA | New | TAYSHA GENE THERAPIES INC | $8,504,000 | – | 320,440 | +100.0% | 2.95% | – |
| RCUS | New | ARCUS BIOSCIENCES INC | $7,788,000 | – | 300,000 | +100.0% | 2.70% | – |
| CALT | New | CALLIDITAS THERAPEUTICS ABsponsered ads | $6,724,000 | – | 200,000 | +100.0% | 2.33% | – |
| FGEN | New | FIBROGEN INC | $5,416,000 | – | 146,014 | +100.0% | 1.88% | – |
| KNSA | New | KINIKSA PHARMACEUTICALS LTD | $5,217,000 | – | 295,238 | +100.0% | 1.81% | – |
| RVMD | New | REVOLUTION MEDICINES INC | $4,994,000 | – | 126,136 | +100.0% | 1.73% | – |
| KURA | New | KURA ONCOLOGY INC | $4,899,000 | – | 150,000 | +100.0% | 1.70% | – |
| ISEE | New | IVERIC BIO INC | $4,699,000 | – | 680,036 | +100.0% | 1.63% | – |
| HLXA | New | HELIX ACQUISITION CORP | $4,548,000 | – | 400,000 | +100.0% | 1.58% | – |
| KRON | New | KRONOS BIO INC | $4,366,000 | – | 146,173 | +100.0% | 1.51% | – |
| JYAC | New | JIYA ACQUISITION CORP | $3,090,000 | – | 300,000 | +100.0% | 1.07% | – |
| VIE | New | VIELA BIO INC | $3,072,000 | – | 85,409 | +100.0% | 1.06% | – |
| IVA | New | INVENTIVA SAads | $2,900,000 | – | 200,000 | +100.0% | 1.00% | – |
| ARQT | New | ARCUTIS BIOTHERAPEUTICS INC | $2,813,000 | – | 100,000 | +100.0% | 0.98% | – |
| NGM | New | NGM BIOPHARMACEUTICALS INC | $2,279,000 | – | 75,227 | +100.0% | 0.79% | – |
| ACRS | New | ACLARIS THERAPEUTICS INC | $2,265,000 | – | 350,000 | +100.0% | 0.78% | – |
| KDMN | New | KADMON HLDGS INC | $1,802,000 | – | 434,114 | +100.0% | 0.62% | – |
| AXSM | New | AXSOME THERAPEUTICS INC | $1,629,000 | – | 20,000 | +100.0% | 0.56% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 33.2% |
| ARCUS BIOSCIENCES INC | 12 | Q3 2023 | 18.1% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 10.1% |
| GOSSAMER BIO INC | 12 | Q3 2023 | 6.2% |
| 4D MOLECULAR THERAPEUTICS IN | 10 | Q1 2023 | 6.6% |
| BRIDGEBIO PHARMA INC | 10 | Q3 2023 | 6.6% |
| AVIDITY BIOSCIENCES INC | 10 | Q1 2023 | 3.8% |
| VERA THERAPEUTICS INC | 9 | Q2 2023 | 3.5% |
| DYNE THERAPEUTICS INC | 9 | Q3 2023 | 3.5% |
| STOKE THERAPEUTICS INC | 9 | Q2 2023 | 3.7% |
View Octagon Capital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-06 |
| SC 13G/A | 2024-02-05 |
| SC 13G | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-25 |
| 13F-HR | 2022-11-14 |
View Octagon Capital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.